BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xie Q, Xuan JW, Tang H, Ye XG, Xu P, Lee IH, Hu SL. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol 2019; 11(5): 421-441 [PMID: 31183003 DOI: 10.4254/wjh.v11.i5.421] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Alotaibi AS, Shamas N, Ansari UU, Sanai FM, Alshahrani A, Fathelrahman AI, Aseeri MA. Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia. J Pharm Bioallied Sci 2021;13:317-24. [PMID: 35017888 DOI: 10.4103/jpbs.jpbs_166_21] [Reference Citation Analysis]
2 Khayat MT, Omar AM, Elfaky MA, Muhammad YA, Felemban EA, El-say KM, El-araby ME, Xie J. Reexamining Povarov Reaction’s Scope and Limitation in the Generation of HCV-NS4A Peptidomimetics. Heteroatom Chemistry 2022;2022:1-12. [DOI: 10.1155/2022/8181543] [Reference Citation Analysis]
3 Li M, Zhuang H, Wei L. How would China achieve WHO's target of eliminating HCV by 2030? Expert Rev Anti Infect Ther 2019;17:763-73. [PMID: 31578079 DOI: 10.1080/14787210.2019.1675509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
4 Chen R, Chen J, Tang Q, Meng Z, Luo L, Zhang W, Deng A, Zhang L, Wang J, Qi T, Zhang R, Shen Y, Liu L, Steinhart C, Lu H. Use of comedications and potential drug-drug interactions in people living with HIV in China. J Infect Chemother 2020;26:722-8. [PMID: 32354599 DOI: 10.1016/j.jiac.2020.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liu J, Zhang Y, Wu B, Wang S, Bin-Chia Wu D, You R. Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China. Front Pharmacol 2021;12:717504. [PMID: 34721016 DOI: 10.3389/fphar.2021.717504] [Reference Citation Analysis]
6 Gan L, Wang D, Bieber B, Mccullough K, Jadoul M, Pisoni RL, Hou F, Liang X, Ni Z, Chen X, Chen Y, Zuo L. Hepatitis C Prevalence, Incidence, and Treatment in Chinese Hemodialysis Patients: Results From the Dialysis Outcomes and Practice Patterns Study-China (2019–21). Front Med 2022;9:910840. [DOI: 10.3389/fmed.2022.910840] [Reference Citation Analysis]
7 He Y, Wang Y, Chen X, Huang H, Deng J, Chen P, Bin H. Performance evaluation of the DAAN HCV assay for quantification of hepatitis C virus RNA and its comparison with COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, v2.0. J Clin Lab Anal 2020;34:e23280. [PMID: 32167624 DOI: 10.1002/jcla.23280] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Dai J, Zhao J, Du Y, McNeil EB, Chongsuvivatwong V. Biomarkers and sociodemographic factors predicting one-year readmission among liver cirrhosis patients. Ther Clin Risk Manag 2019;15:979-89. [PMID: 31496713 DOI: 10.2147/TCRM.S203883] [Reference Citation Analysis]